BSc Biol, PhD Molecular Oncology
monica.martinez@iisgaliciasur.es
Tel: 986 217 463
Our research unit is formed by a multidisciplinary team composed of biologists, medical oncologists and pathologists with the common objective of understanding the molecular alterations involved in cancer to help in patients´ diagnosis and prognosis.
We have currently several projects on going aimed to find new biomarkers and molecular targets that can be used towards a precision medicine, opening new avenues in the therapeutic options, using tissue and liquid biopsies. We believe that our work is predestined to have a clear clinical application that could change cancer diagnosis and would help oncologists for personalized treatments.
• 2021 to present: Miguel Servet Researcher (ISCIII), Galicia Sur Health Research Institute (Hospital Álvaro Cunqueiro of Vigo, Spain)
• 2022 to present: Member of IISGS Equality Observatory, Galicia Sur Health Research Institute (Hospital Álvaro Cunqueiro of Vigo, Spain)
• 2018-2020: AECC investigator. Genomes and Disease lab, CIMUS (Santiago de Compostela, Spain)
• 2016: Jose Castillejo MECDE fellowship. Expression Regulation in Cancer lab. I3S & IPATIMUP, Porto (Portugal)
• 2014-2017: Postdoct. Molecular and Cellular Oncology lab. Biomedical Research Institute, Hospital Universitario 12 de Octubre (Madrid, Spain)
• 2014: EMBO Short-term Fellowship. Medical Genomics lab. Cancer Institute, UCL (London, UK)
• 2011-2014: Juan de la Cierva Postdoctoral MICINN Fellow. Molecular Oncology Unit, CIEMAT (Madrid, Spain)
• 2010: Postdoct. ECIMAT-CIBIO (Vigo, Spain – Porto, Portugal)
• 2005-2009: FPI PhD student (MINECO fellowship). Population Genetics and Cytogenetics Group (XB2). Universidade de Vigo (Vigo, Spain)
PREDOC STUDENTS
RESEARCH SUPPORT BIOINFORMATICIAN
MASTER’S STUDENT
• Manuel Pino González
LAB ASSISTANT
• Irene Alonso Álvarez, IISGS
EXTERNAL Cols
CHUS – Oncología Médica
• Dr. Luis León
• Dr Urbano Anido
CHUS – Anatomía Patológica
• Dr. Máximo Fraga
• Dr. Ihab Abdulkader
Hospital 12 de Octubre
• Dr. Jesús Paramio
• Dr. Cristian Suarez
CiMUS
• Dr. Jose Tubio
ONCOMET
• Dra. Laura Muinelo
• Dra. Clotilde Costa
INSTITUTO PORTUGUÊS DE ONCOLOGIA
• Dra. Carmen Jerónimo
• Suarez-Cabrera C, Estudillo L, Ramón-Gil E, Martínez-Fernández M, Peral J, Rubio C, Lodewijk I, Martín de Bernardo A, García-Escudero R, Villacampa F, Duarte J, de la Rosa F, Castellano D, Guerrero-Ramos F, Real FX, Malats N, Paramio JM, Dueñas M. BlaDimiR: A urine-based miRNA score for accurate bladder cancer diagnosis and follow-up. European Urology, in press (2022).
• Oitabén A, Fonseca P, Villanueva MJ, García-Benito C, López-López A, Garrido-Fernández A, González-Ojea C, Juaneda-Magdalena L, Lázaro ME, Martínez-Fernández M. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. Cancers (Basel), 14: 2626 (2022).
• Álvarez EG, Demeulemeester J*, Otero P*, Jolly C*, García-Souto D*, Pequeño-Valtierra A, Zamora J, Tojo M, Temes J, Baez-Ortega A, Rodriguez-Martin B, Oitaben A, Bruzos AL, Martínez-Fernández M, et al Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun,12: 6910 (2021).
• Segovia*, San José-Enériz* , Munera-Maravilla*, Martínez-Fernández M et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 25: 1073–1081 (2019)
• Rubio C*; Martinez-Fernandez M*; et al. Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status. Clinical Cancer Research. 25, pp. 390 – 402 (2019)
• Dueñas, Perez-Figueroa…,Mónica Martínez-Fernández. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Scientific Reports, 9: 10362 (2019)
• Martínez Fernández M et al. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 6 – 39, pp. 42258 – 42333 (2015)
• Martínez Fernández M et al. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clinical Epigenetics. 7, pp. 109 (2015)
• Santos M*; Martínez Fernández M* et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Research. 74 – 22, pp. 6565 – 6642 (2014)
• Proyectos de excelencia, Axencia Galega de Innovación (Xunta de Galicia) “El potencial de la epigenética y el fenotipo inmune circulante en la respuesta a la inmunoterapia” (2022-2026)
• Proyecto de Investigación en Salud del ISCIII, AES2021, “UNA PERSPECTIVA EPIGENÉTICA EN LA ERA DE LA INMUNOONCOLOGIA”, (2022-2024)
• Proyecto Miguel Servet ISCIII: “Searching for potential predictive biomarkers for immunotherapy”, (2020-2024)
• Ideas Semilla AECC: “Estudio de nuevos mecanismos moleculares en la respuesta a inmmunoterapia”, (2020-2022)
• OCTOPUS project: Oncoloxía Customizada para Tratar Os PUlmónS (https://proxectooctopus.org/) funded by the Vigo Against Cancer Association, (2020-)
• Proyecto de Investigación en Salud del ISCIII, AES2019, “Ampliando el horizonte para los biomarcadores predictores de respuesta a inmmunoterapia”, (2020)
• AECC Investigator “Estudio del impacto funcional de la transducción de secuencias reguladoras mediada por retrotransposones altamente mutagénicos” (2018-2020).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.